Dorn et al have reported that, the PD‐L1 level is upregulated within primary human hepatocytes using the hepatocellular lipid accumulation model in vitro, while it is confirmed through human liver specimen analysis that, PD‐1 and PD‐L1 levels are upregulated among NASH cases, which emphasizes the potential effect of aberrant lipid metabolism on immune checkpoint expression.41 The gene discussed is PDCD1; the disease is metabolic dysfunction-associated steatohepatitis.